After a deadly clinical trial, will immune therapies for cancer be a bust?
By Damian Garde,
STAT
| 07. 08. 2016
Immune therapies have been hailed as the future of cancer treatments, with new drugs racking up excellent clinical results by turning the body’s natural defenses on tumors.
But Thursday’s news that three patients died in a trial of one such treatment has surprised oncologists and biotech investors, casting doubts on what looked like a blockbuster new approach to fighting cancer.
Here’s a rundown on the fatal trial and what it means for the rest of the field.
Continue reading on STAT
Image via Flickr/NIH Image Gallery
Related Articles
By Riley Beggin and Jeff Stein, The Washington Post | 08.03.2025
The White House does not plan to require health insurers to provide coverage for in vitro fertilization services, two people with knowledge of internal discussions said, even though the idea was one of President Donald Trump’s key campaign pledges.
Last...
By Sayantani DasGupta, MedPage Today | 08.05.2025
It's just a jeans ad.
It's not that deep.
It's just social media outrage.
Should physicians care about the recent American Eagle "Sydney Sweeney Has Good Genes Jeans" controversy? What, if anything, does the provocative campaign have to...
By Editors, Nature | 08.15.2025
A technology that played a key part in saving millions of lives during the COVID-19 pandemic1 should be feted to the skies. Instead, US health secretary Robert F. Kennedy Jr announced last week that the US federal government is...
By Staff, National Women's Law Center | 08.13.2025
INTRODUCTION
Baby bonuses. Motherhood medals. Fertility tracking. You may have heard of these policy proposals as solutions from the Trump administration to help encourage women to have more children.
Besides falling short of ensuring that people have what they need...
